title: Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
authors.forename: N
authors.initials: N
authors.lastname: Pastor
authors.forename: I
authors.initials: I
authors.lastname: Betlloch
authors.forename: J C
authors.initials: JC
authors.lastname: Pascual
authors.forename: M
authors.initials: M
authors.lastname: Blanes
authors.forename: J
authors.initials: J
authors.lastname: Bañuls
authors.forename: J F
authors.initials: JF
authors.lastname: Silvestre
mesh_terms: D000369:Aged, 80 and over; D000068800:Etanercept; D005260:Female; D016523:Foot Ulcer / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept